Gni Ltd (GNIXF) 1.8900 $GNIXF Kidney Fibrosis - Pipeline

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gni Ltd (GNIXF) 1.8900 $GNIXF

Kidney Fibrosis - Pipeline Review 2015
M2 - Wed Jan 06, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/gj84k6/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to Buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Develop strategic initiatives by understanding the focus areas of leading companies. - Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis. - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Cellmid Limited - Evotec AG - Galectin Therapeutics, Inc. - GenKyoTex S.A. - GNI Group Ltd. - Intercept Pharmaceuticals, Inc. - Isarna Therapeutics GmbH - Lpath, Inc. - MorphoSys AG - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - SciFluor Life Sciences, LLC For more information visit http://www.researchandmarkets.com/research/gj...y_fibrosis
RPTP: 7.30 (-0.06), GALT: 1.99 (+0.05), ICPT: 167.07 (+0.53), RGLS: 3.44 (-0.03), ABBV: 66.17 (-0.84), LPTN: 2.68 (-0.50)

World Liver Cirrhosis Therapeutics Pipeline Review, H2 2015 - 13 Companies & 24 Drug Profiles
M2 - Fri Dec 11, 6:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/f583cg/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Human Stem Cells Institute - Nimbus Therapeutics, LLC - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited Drug Profiles - (sofosbuvir velpatasvir) - Cell Therapy for Liver Cirrhosis - DB-027 - DB-036 - emricasan - F-351 - Gemacell - GR-MD-01 - GR-MD-02 - GXHPC-1 - Livercellgram - Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Cirrhosis - ND-654 - Px-104 - rifaximin - simtuzumab - Stem Cell Therapy for Liver Cirrhosis - Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Stem Cell Therapy for Metabolic, Gastrointestinal and Respiratory Disorders - Stem Cell Therapy for Rheumatoid Arthritis and Liver Cirrhosis - Stempeucel - STNM-04 - thrombopoietin - Undisclosed Peptide for Liver Cirrhosis For more information visit http://www.researchandmarkets.com/research/f5..._cirrhosis
GILD: 81.47 (+0.55), CNAT: 1.93 (unch), GALT: 1.99 (+0.05)

Liver Fibrosis - Pipeline Review, H1 2015 - Featuring 23 Therapeutics Companies
M2 - Thu Jun 11, 10:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7lgbpl/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advinus Therapeutics Ltd. - Angion Biomedica Corp. - BerGenBio AS - BiOrion Technologies B.V. - Celgene Corporation - Digna Biotech, S.L. - FibroGen, Inc. - Galectin Therapeutics, Inc. - Genfit SA - GenKyoTex S.A. - Gilead Sciences, Inc. - GNI Group Ltd. - La Jolla Pharmaceutical Company - LG Life Sciences, Ltd. - Nitto Denko Corporation - Pharmaxis Limited - Promedior, Inc. - Promethera Biosciences S.A. - ProMetic Life Sciences Inc. - RXi Pharmaceuticals Corporation - TCM Biotech International Corp - Vascular Biogenics Ltd. - Virobay Inc. For more information visit http://www.researchandmarkets.com/research/7l...r_fibrosis
GILD: 81.47 (+0.55), GALT: 1.99 (+0.05), FGEN: 19.11 (+0.06), VBAY: (), VBLT: 4.10 (unch), CELGZ: 1.15 (-0.15)

Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 81.47 (+0.55), CNAT: 1.93 (unch), GALT: 1.99 (+0.05)

Kidney Fibrosis - Pipeline Review, H1 2015 - 13 Companies & 19 Drug Profiles
M2 - Wed Jun 10, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qhppdp/kidney_fibrosis) has announced the addition of the "Kidney Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Angion Biomedica Corp. - Bio-inRen - BioLineRx, Ltd. - BiOrion Technologies B.V. - Galectin Therapeutics, Inc. - GNI Group Ltd. - Lpath, Inc. - ProMetic Life Sciences Inc. - Raptor Pharmaceuticals Corp. - Regulus Therapeutics Inc. - RestorGenex Corporation - Tobira Therapeutics, Inc. Drug Profiles - ANG-3298 - ANG-4011 - BOT-191 - BRN-1889 - cenicriviroc mesylate - CGEN-856 - CT-140 - cysteamine DR - F-351 - Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - GR-MD-02 - ICG-001 - LJ-1888 - Lpathomab - P-007 - P-529 - PBI-4050 - RG-012 - Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis For more information visit http://www.researchandmarkets.com/research/qh...y_fibrosis
RPTP: 7.30 (-0.06), GALT: 1.99 (+0.05), RGLS: 3.44 (-0.03), ABBV: 66.17 (-0.84), TBRA: 4.85 (-0.03), LPTN: 2.68 (-0.50)

Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.99 (+0.05), LLY: 79.57 (+0.28), GSK: 44.41 (+0.29), BMY: 59.86 (+0.60), CTIC: 0.35 (-0.01), CNCE: 10.94 (+0.13), JNJ: 119.44 (+0.31), GILD: 81.47 (+0.55), AZN: 33.83 (-0.02), CCXI: 4.61 (-0.03), ICPT: 167.07 (+0.53), ABBV: 66.17 (-0.84)

Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com
PRWeb - Tue May 05, 5:21AM CDT
The report "Liver Fibrosis - Pipeline Review, H2 2014" provides comparative analysis on the therapeutic development for Liver Fibrosis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/liver-fibros...eport.html .
GILD: 81.47 (+0.55), PFE: 35.09 (+0.25), GALT: 1.99 (+0.05), FGEN: 19.11 (+0.06), CELGZ: 1.15 (-0.15)

GNI Group Ltd. - Product Pipeline Review - 2014
M2 - Fri Apr 17, 3:37AM CDT
Product Pipeline Review - 2014

Liver Fibrosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/wmnbdp/liver_fibrosis) has announced the addition of the "Liver Fibrosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Fibrosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Genzyme - Gilead Sciences - Bioneer - FibroGen - Silence Therapeutics - Celgene - Nitto Denko - Genfit - Pharmaxis - La Jolla Pharmaceutical - ProMetic Life Sciences - LG Life Sciences - Digna Biotech - Advinus Therapeutics - Promedior - GenKyoTex - Angion Biomedica - Virobay - Intercept Pharmaceuticals - Tobira Therapeutics - GNI Group - Promethera Biosciences - BiOrion Technologies - ACROVIS biostructures - RXi Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/wm...r_fibrosis
GILD: 81.47 (+0.55), ICPT: 167.07 (+0.53), TBRA: 4.85 (-0.03), CELGZ: 1.15 (-0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 0

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 156

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 395

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 145

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 22

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 149

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Wells Fargo's Insight on Industrial Stocks Amid Elections

Updated Category News Views 231

Wells Fargo's Industrial Sector Election Guide As the US presidential election approaches, Wells Fargo has closely examined the Industrials sector, pinpointing potential winners and those stocks that may face challenges. This analysis is particularly noteworthy given the significant changes in policy that may arise depending on the election outcome. Key Areas of Focus in...

Continue Reading
Woodward Secures Airbus Supplier Role for A350 Actuation System

Updated Category News Views 318

Woodward Partners with Airbus for A350 Spoiler Actuation Woodward, a prominent player in aerospace and energy control solutions, has been selected as a key supplier for Airbus's A350 Spoiler Actuation System. This collaboration marks another significant milestone in their long-standing relationship, demonstrating Woodward’s commitment to providing top-notch technology...

Continue Reading
GreenPower Motor Company Secures Significant Loan for Growth

Updated Category News Views 327

GreenPower Motor Company Announces Successful Loan Closure GreenPower Motor Company Inc. (NASDAQ: GP) has officially completed the third tranche of its secured term loan offering, securing an impressive aggregate principal amount of U.S. $300,000. The company specializes in designing and distributing all-electric, purpose-built, zero-emission vehicles tailored for various...

Continue Reading
Carrier Global's Strategic Moves to Enhance Market Growth

Updated Category News Views 383

Understanding Carrier Global's Transformation Journey Carrier Global Corporation (NYSE: CARR) is a leading entity in the heating, ventilation, and air conditioning (HVAC) industry, known for its ongoing transformation since its spin-off in 2020. This article delves into the company’s strategic maneuvers, financial trajectory, and competitive positioning to inform...

Continue Reading
International School of Permanent Makeup Enhances Education Offerings

Updated Category News Views 252

International School of Permanent Makeup Unveils New Website The International School of Permanent Makeup (ISPMU) has officially launched its redesigned website, providing an updated platform for aspiring beauty professionals to explore advanced certification courses. This move reflects ISPMU's commitment to delivering top-quality education in the permanent makeup field....

Continue Reading